Statement: the evaluation of results in the primary clinical trial is gauged by the duration a patient lives with the illness, during and post treatment.
Primary_evidence: Outcome Measurement:    Progression-free Survival (PFS) and to Evaluate Safety of the Trastuzumab, Bevacizumab and Docetaxel Regimen.   The trial was designed as a single-stage phase II rather then usual two-stage design because of the progression free survival (PFS) primary endpoint, as it is impractical to wait to assess PFS for patients in the first stage. We will consider a PFS of 50% at twelve months (median PFS of 12 months) or less uninteresting and a PFS of 70% at twelve months (median PFS of twenty months) worthy of pursuing the regimen in a future trials. The single-stage design is as follows: p0=0.50, p1=0.70, α=0.10, β= 0.10. This leads to a total sample size of 39 patients, 24 or higher of who are progression-free at 12 months.   Time frame: up to 3 years Results 1:    Arm/Group Title: Trastuzumab, Bevacizumab, and Docetaxel   Arm/Group Description: Trastuzumab [6mg/kg], Bevacizumab [15mg/kg], and Docetaxel [75 mg/M ]   Overall Number of Participants Analyzed: 26   Median (95% Confidence Interval)   Unit of Measure: months  14.3        (9.3 to 35)